A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.
Lung cancer remains the leading cause of cancer death in the United States, largely because it is most often diagnosed at an advanced stage.
Bayard “Barney” Clarkson, a pioneering leukemia researcher, a career-long member of the faculty of Memorial Sloan Kettering Cancer Center, and past president of the American Society of Clinical Oncology and the American Association for Cancer Research, died on Dec. 30.
Paul F. Engstrom, a well-respected, longtime member of our Fox Chase Cancer Center community, died Dec. 26. He was 89.
David Mitchell, a tireless patient advocate whose lived experience with multiple myeloma shaped a decade of courageous leadership on behalf of patients nationwide, died Jan. 2. He was 75.
Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.
Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity. Except for the elimination of the Plan to Enhance Diversity component and lengthening of the Shared Resource write-ups from three to six pages, the guidelines are essentially unchanged.
New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.
2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission.
